Alivus Life Sciences Limited (ALIVUS.NS)
- Previous Close
1,033.60 - Open
1,033.60 - Bid --
- Ask --
- Day's Range
996.50 - 1,040.50 - 52 Week Range
850.00 - 1,251.00 - Volume
100,923 - Avg. Volume
114,782 - Market Cap (intraday)
127.5B - Beta (5Y Monthly) 0.19
- PE Ratio (TTM)
28.93 - EPS (TTM)
35.96 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date Oct 17, 2023
- 1y Target Est
1,296.25
Alivus Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers various APIs, such as olmesartan, telmisartan, perindopril, atovaquone, solifenacin, mirabegron, sitagliptin, zonisamide, adapalene, and rosuvastatin. It also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. The company's APIs are used in various therapeutic segments, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, and anti-infectives. It also exports its products to Europe, North America, Latin America, Japan, and internationally. The company was formerly known as Glenmark Life Sciences Limited and changed its name to Alivus Life Sciences Limited in December 2024. The company was incorporated in 2011 and is based in Mumbai, India. Alivus Life Sciences Limited is a subsidiary of Nirma Limited.
www.alivus.com2,014
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: ALIVUS.NS
View MorePerformance Overview: ALIVUS.NS
Trailing total returns as of 4/25/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALIVUS.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALIVUS.NS
View MoreValuation Measures
Market Cap
126.89B
Enterprise Value
121.74B
Trailing P/E
28.84
Forward P/E
21.23
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.85
Price/Book (mrq)
5.00
Enterprise Value/Revenue
5.60
Enterprise Value/EBITDA
18.64
Financial Highlights
Profitability and Income Statement
Profit Margin
19.42%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
22.74B
Net Income Avi to Common (ttm)
4.42B
Diluted EPS (ttm)
35.96
Balance Sheet and Cash Flow
Total Cash (mrq)
4.46B
Total Debt/Equity (mrq)
0.63%
Levered Free Cash Flow (ttm)
--